S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

MACK Merrimack Pharmaceuticals Inc

15.00

-0.03 (-0.20%)

04 May 2024 - Closed

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Merrimack Pharmaceuticals Charts.

Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Merrimack Pharmaceuticals Charts.

Merrimack Pharmaceuticals Inc News

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Wednesday 1 May 2024 (4 days ago) • Business Wire

Merrimack Receives $225 Million Milestone Payment from Ipsen
Thursday 28 March 2024 (1 month ago) • Business Wire

Form 425 - Prospectuses and communications, business combinations
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Merrimack Reports Full Year 2023 Financial Results
Friday 8 March 2024 (2 months ago) • Business Wire

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Wednesday 14 February 2024 (3 months ago) • Business Wire

More Merrimack Pharmaceuticals Inc News Articles

Verizon Communications

JP Morgan Chase

Gold vs US Dollar

Australian SE All Ordina...

S&P ASX 300 Metals and M...

Invesco QQQ Trust Series 1

Sterling vs AUD

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions